Results 31 to 40 of about 304,289 (334)

Review of therapeutic mechanisms and applications based on SARS-CoV-2 neutralizing antibodies

Frontiers in Microbiology, 2023
COVID-19 pandemic is a global public health emergency. Despite extensive research, there are still few effective treatment options available today. Neutralizing-antibody-based treatments offer a broad range of applications, including the prevention and ...
Mingtao Liu, Hui Gan, Zhiman Liang, Li Liu, Qiwen Liu, Yiyin Mai, Huihuang Chen, Baoying Lei, Shangwei Yu, Huihui Chen, Peiyan Zheng, Baoqing Sun   +11 more
doaj   +1 more source

SnapShot: Broadly Neutralizing Antibodies

Cell, 2013
Durably elicited by live attenuated virus, less durably by inactivated virusConserved bnAb epitopes:1) Ep1 (res. 380–400) 2) Ep2 (res. 190–200)3) Ep3 (res. 571–579)Despite the extensive variability of measles virus, nAb responses to vaccination are broad becausethe conserved epitopes are immunoprominent.May relate to overlap of the receptor-binding ...
Brian Moldt, Devin Sok, Dennis R. Burton
openaire   +3 more sources

Generation of a protective murine monoclonal antibody against the stem of influenza hemagglutinins from group 1 viruses and identification of resistance mutations against it.

PLoS ONE, 2019
Vaccines that elicit broadly cross-neutralizing antibodies, including antibodies that target the conserved stem of hemagglutinin (HA), are being developed as a strategy for next-generation influenza vaccines that protect against influenza across multiple
Wei Wang, Russell Vassell, Hyo Sook Song, Qiong Chen, Paul W Keller, Swati Verma, Esmeralda Alvarado-Facundo, Hongquan Wan, Falko Schmeisser, Clement A Meseda, Jerry P Weir, Carol D Weiss   +11 more
doaj   +1 more source

Antibody Profiling of Microbial Antigens in the Blood of COVID-19 mRNA Vaccine Recipients Using Microbial Protein Microarrays

Vaccines, 2023
Although studies have demonstrated that infections with various viruses, bacteria, and parasites can modulate the immune system, no study has investigated changes in antibodies against microbial antigens after the COVID-19 mRNA vaccination.
Hiroaki Saito, Hiroki Yoshimura, Makoto Yoshida, Yuta Tani, Moe Kawashima, Taiga Uchiyama, Tianchen Zhao, Chika Yamamoto, Yurie Kobashi, Toyoaki Sawano, Seiya Imoto, Hyeongki Park, Naotoshi Nakamura, Shingo Iwami, Yudai Kaneko, Aya Nakayama, Tatsuhiko Kodama, Masatoshi Wakui, Takeshi Kawamura, Masaharu Tsubokura   +19 more
doaj   +1 more source

Infection with chikungunya virus confers heterotypic cross-neutralizing antibodies and memory B-cells against other arthritogenic alphaviruses predominantly through the B domain of the E2 glycoprotein.

PLoS Neglected Tropical Diseases, 2023
Infections with Chikungunya virus, a mosquito-borne alphavirus, cause an acute febrile syndrome often followed by chronic arthritis that persists for months to years post-infection.
John M Powers, Zoe L Lyski, Whitney C Weber, Michael Denton, Magdalene M Streblow, Adam T Mayo, Nicole N Haese, Chad D Nix, Rachel Rodríguez-Santiago, Luisa I Alvarado, Vanessa Rivera-Amill, William B Messer, Daniel N Streblow   +12 more
doaj   +1 more source

Kinetics of the neutralizing antibody response to respiratory syncytial virus infections in a birth cohort [PDF]

, 2013
The kinetics of respiratory syncytial virus (RSV) neutralizing antibodies following birth, primary and secondary infections are poorly defined. The aims of the study were to measure and compare neutralizing antibody responses at different time points in ...
Cane, Patricia, Medley, Graham, Mutunga, M. N., Nokes, D. James, Okiro, Emelda A., Sande, Charles J.   +5 more
core   +1 more source

TIV vaccination modulates host responses to influenza virus infection that correlate with protection against bacterial superinfection [PDF]

, 2019
Background: Influenza virus infection predisposes to secondary bacterial pneumonia. Currently licensed influenza vaccines aim at the induction of neutralizing antibodies and are less effective if the induction of neutralizing antibodies is low and/or the
Choi, Angela, Christopoulou, Ioanna, García-Sastre, Adolfo, Saelens, Xavier, Schotsaert, Michael   +4 more
core   +2 more sources

Feline Immunodeficiency Virus (FIV) Neutralization: A Review

Viruses, 2011
One of the major obstacles that must be overcome in the design of effective lentiviral vaccines is the ability of lentiviruses to evolve in order to escape from neutralizing antibodies.
Margaret J. Hosie, Daniela Pajek, Brian J. Willett, Ayman Samman   +3 more
doaj   +1 more source

Discovery of neutralizing SARS-CoV-2 antibodies enriched in a unique antigen specific B cell cluster.

PLoS ONE, 2023
Despite development of effective SARS-CoV-2 vaccines, a sub-group of vaccine non-responders depends on therapeutic antibodies or small-molecule drugs in cases of severe disease.
Stine Sofie Frank Lende, Nanna Møller Barnkob, Randi Westh Hansen, Harsh Bansia, Mike Vestergaard, Frederik Holm Rothemejer, Anne Worsaae, Deijona Brown, Maria Lange Pedersen, Anna Halling Folkmar Rahimic, Anna Karina Juhl, Torben Gjetting, Lars Østergaard, Amédée Des Georges, Laurent-Michel Vuillard, Mariane Høgsbjerg Schleimann, Klaus Koefoed, Martin Tolstrup   +17 more
doaj   +1 more source

HIV-1 neutralizing antibodies elicited in humans by a prefusion-stabilized envelope trimer form a reproducible class targeting fusion peptide

Cell Reports, 2023
Summary: Elicitation of antibodies that neutralize the tier-2 neutralization-resistant isolates that typify HIV-1 transmission has been a long-sought goal.
Shuishu Wang, Flavio Matassoli, Baoshan Zhang, Tracy Liu, Chen-Hsiang Shen, Tatsiana Bylund, Timothy Johnston, Amy R. Henry, I-Ting Teng, Prabhanshu Tripathi, Jordan E. Becker, Anita Changela, Ridhi Chaudhary, Cheng Cheng, Martin Gaudinski, Jason Gorman, Darcy R. Harris, Myungjin Lee, Nicholas C. Morano, Laura Novik, Sijy O’Dell, Adam S. Olia, Danealle K. Parchment, Reda Rawi, Jesmine Roberts-Torres, Tyler Stephens, Yaroslav Tsybovsky, Danyi Wang, David J. Van Wazer, Tongqing Zhou, Nicole A. Doria-Rose, Richard A. Koup, Lawrence Shapiro, Daniel C. Douek, Adrian B. McDermott, Peter D. Kwong   +35 more
doaj   +1 more source